Header Logo

Connection

Joan Lo to Bone Density Conservation Agents

This is a "connection" page, showing publications Joan Lo has written about Bone Density Conservation Agents.
Connection Strength

6.232
  1. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. BMC Musculoskelet Disord. 2020 Dec 03; 21(1):801.
    View in: PubMed
    Score: 0.720
  2. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int. 2019 Dec; 30(12):2515-2520.
    View in: PubMed
    Score: 0.663
  3. Vitamin D Status Among Older Women Initiating Osteoporosis Therapy. J Am Geriatr Soc. 2019 10; 67(10):2207-2208.
    View in: PubMed
    Score: 0.658
  4. Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. J Manag Care Spec Pharm. 2019 Jun; 25(6):719-723.
    View in: PubMed
    Score: 0.648
  5. Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System. J Manag Care Spec Pharm. 2017 Apr; 23(4):503-512.
    View in: PubMed
    Score: 0.558
  6. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone. 2012 Sep; 51(3):524-7.
    View in: PubMed
    Score: 0.398
  7. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg. 2012 Aug; 70(8):1844-53.
    View in: PubMed
    Score: 0.398
  8. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg. 2010 Sep; 68(9):2232-40.
    View in: PubMed
    Score: 0.353
  9. Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. J Oral Maxillofac Surg. 2010 Mar; 68(3):508-14.
    View in: PubMed
    Score: 0.341
  10. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010 Feb; 68(2):243-53.
    View in: PubMed
    Score: 0.331
  11. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009 Jul; 67(7):1363-72.
    View in: PubMed
    Score: 0.326
  12. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17(6):922-8.
    View in: PubMed
    Score: 0.261
  13. The Epidemiology of Metatarsal Fractures Among Older Females With Bisphosphonate Exposure. J Foot Ankle Surg. 2020 Mar - Apr; 59(2):269-273.
    View in: PubMed
    Score: 0.171
  14. Determinants of Oral Bisphosphonate Use Beyond 5 Years. J Manag Care Spec Pharm. 2020 Feb; 26(2):197-202.
    View in: PubMed
    Score: 0.170
  15. Changing Patterns in Oral Bisphosphonate Initiation in Women between 2004 and 2012. J Am Geriatr Soc. 2017 03; 65(3):656-658.
    View in: PubMed
    Score: 0.138
  16. Clinical correlates of atypical femoral fracture. Bone. 2012 Jul; 51(1):181-4.
    View in: PubMed
    Score: 0.098

© 2024 Kaiser Permanente